| Name | Title | Contact Details |
|---|
MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
ConjuGon Inc is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics` first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic which completed a two-cohort phase 2 clinical trial and a small molecule imaging agent that has also completed a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra™, an ultra-orphan radiotherapy candidate currently in a phase 2 study under an SPA. Progenics’ first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Ltd., a Valeant Pharmaceuticals International, Inc.
Marina Biotech`s focus is to treat the intersection of arthritis, pain, hypertension, and oncology diseases using combination therapies of already approved drugs. The company is developing and commercializing late stage, non-addictive pain therapeutics. The company`s `next-generation of celecoxib,` including IT-102 and IT-103, are designed to control the dangerous side-effect of edema that prohibits the drug from being prescribed at higher doses. These have the potential of replacing opioids and combating the opioid epidemic. They are also being developed as anticancer agents against FAP and CRC. On the Sales and Marketing front- we are actively promoting sales and distribution of our FDA approved drug- Prestalia- through our patient centric care program: 1) We have developed a patented total care program which increase compliance to over 80%. 2) Increase compliance is expected to improve care for hypertensive patients, especially resistant hypertensive patients which currently have no treatment available to them. 3) Resistant hypertension market size is large with 22% of all hypertensive pts eventually become resistant hypertension 4) Compliance/counseling has been shown clinically to treated resistant hypertensive patients 5) Deep pipeline a. Perindopril- Hypertension monotherapy. ACEON (Perindopril) NDA b. Prestalia- Hypertension combination therapy. i. Perindopril/Amlodipine, ii. 1st line hypertension, c. Atorvastatin/Perindopril: Hypertension and lipid disorder d. Pipeline drug: Hypertension and Pain. IT-102, IT-103
At Alveo we understand the importance of access to cutting-edge molecular testing and cloud-based data analytics for rapid diagnosis and management of infectious diseases. With an initial focus on acute respiratory infections including COVID-19, Flu A/B and RSV, Alveo`s agile and dynamic molecular diagnostic platform, be.well™, can be adapted to detect a wide range of diseases, bacteria, and other pathogens that threaten public health, across all modalities. We believe increased access to real-time test results will transform the way individuals, healthcare providers and public health professionals identify and manage infectious diseases. With be.well™, we will Know Sooner, Act Faster™.